Columnist Desiree Lama has accepted her MS diagnosis as part of her identity — but it's not the only thing that defines her, ...
Among 282 patients with pediatric-onset MS, 39% started high-efficacy therapy early (at ages 12-17), and 61% started late ...
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...
A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS).
A study presented at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple ...
"Those with the highest burden of comorbidity had over a 30% increased risk of having disability worsening," Salter said. "In ...
New research presented today at ECTRIMS 2024 reveals that initiating monoclonal antibody therapy during childhood, rather than delaying treatment until early adulthood, significantly reduces long-term ...
New research presented today at European Committee for Treatment and Research in Multiple Sclerosis 2024 reveals that ...
The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...
Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback